Related Experiment Video
Updated: Jul 10, 2026

Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
Floating dosage forms to prolong gastro-retention--the characterisation of calcium alginate beads
Frances Stops1, John T Fell, John H Collett
1GlaxoSmithKline Pharmaceuticals, Park Road, Ware SG12 0DP, UK. frances.x.stops@gsk.com
Abstract:
Floating calcium alginate beads, designed to improve drug bioavailability from oral preparations compared with that from many commercially available and modified release products, have been investigated as a possible gastro-retentive dosage form. A model drug, riboflavin, was also incorporated into the formula. The aims of the current work were (a) to obtain information regarding the structure, floating ability and changes that occurred when the dosage form was placed in aqueous media, (b) to investigate riboflavin release from the calcium alginate beads in physiologically relevant media prior to in vivo investigations. Physical properties of the calcium alginate beads were investigated. Using SEM and ESEM, externally the calcium alginate beads were spherical in shape, and internally, air filled cavities were present thereby enabling floatation of the beads. The calcium alginate beads remained buoyant for times in excess of 13h, and the density of the calcium alginate beads was <1.000gcm(-3). Riboflavin release from the calcium alginate beads showed that riboflavin release was slow in acidic media, whilst in more alkali media, riboflavin release was more rapid. The characterisation studies showed that the calcium alginate beads could be considered as a potential gastro-retentive dosage form.
Related Concept Videos
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Oral Drug Delivery Systems: Delayed-Release Systems
Oral Drug Delivery Systems: Continuous-Release Systems
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Modified-Release Drug Delivery Systems: Rate-Programmed I
